Primecap Management Co. CA Increases Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Primecap Management Co. CA grew its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 5.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,232,340 shares of the company’s stock after acquiring an additional 67,730 shares during the quarter. Primecap Management Co. CA owned about 1.74% of Zentalis Pharmaceuticals worth $5,040,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Eventide Asset Management LLC boosted its holdings in Zentalis Pharmaceuticals by 47.9% during the 4th quarter. Eventide Asset Management LLC now owns 11,559,975 shares of the company’s stock valued at $175,134,000 after acquiring an additional 3,745,936 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Zentalis Pharmaceuticals by 20.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,489,709 shares of the company’s stock worth $54,999,000 after purchasing an additional 585,644 shares during the period. Decheng Capital LLC bought a new position in shares of Zentalis Pharmaceuticals in the 4th quarter worth about $31,809,000. Renaissance Technologies LLC raised its position in shares of Zentalis Pharmaceuticals by 152.6% in the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after purchasing an additional 399,745 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Zentalis Pharmaceuticals by 0.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 445,823 shares of the company’s stock worth $6,754,000 after buying an additional 3,759 shares during the last quarter.

Zentalis Pharmaceuticals Price Performance

Shares of Zentalis Pharmaceuticals stock opened at $4.16 on Thursday. The stock’s 50 day simple moving average is $3.54 and its 200-day simple moving average is $8.54. The stock has a market cap of $295.82 million, a P/E ratio of -1.25 and a beta of 1.70. Zentalis Pharmaceuticals, Inc. has a 1-year low of $2.83 and a 1-year high of $23.12.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Friday, August 9th. The company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.40). During the same quarter in the prior year, the business earned ($1.85) EPS. As a group, research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.95 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ZNTL. Stifel Nicolaus decreased their price objective on shares of Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, June 18th. Wedbush upgraded shares of Zentalis Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $4.00 price target on the stock in a research note on Monday, August 12th. Wells Fargo & Company cut Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $29.00 to $9.00 in a report on Tuesday, June 18th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Monday, August 12th. Finally, Oppenheimer reissued an “outperform” rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Monday. Seven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $10.78.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.